Dacarbazine or Temozolomide

Phase 2Small molecule

Dacarbazine or Temozolomide is one of 27 small molecule programs targeting Mucosal Melanoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mucosal MelanomaActive, not recruiting

Mucosal MelanomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Mucosal Melanoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

6 2

Opdivo

Bristol-Myers Squibb

Phase 2

4 3

Lenvima

Eisai

Phase 2

3 4

Yervoy

Bristol-Myers Squibb

Phase 2

2 5

Taxol

Teva

Phase 2

1 6

Tecentriq

Roche

Phase 2

1 7

Cabometyx

Avastin

2 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 10

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Mucosal Melanoma

NCT07400302

Clinical

Trials by Indication[1]

Mucosal Melanoma1 trial

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery

Recruiting·TThe First Hospital of Jilin University·Phase 2·NCT07400302·220 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dacarbazine or Temozolomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dacarbazine or Temozolomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dacarbazine or Temozolomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Hospital of Jilin University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe First Hospital of Jilin University

Dacarbazine or Temozolomide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Mucosal Melanoma1 trial

References

Drug Info

Quick Facts

Related News